

‘An Alliance of Members of the European Parliament advocating to make migraine a European priority and improve the lives of people living with migraine across the European Union’

What is Migraine?

Migraine is not just a bad headache. It is a serious, distinct and complex neurological disease. There are different kinds of migraine. Their common feature is that they affect people from a young age to adulthood.

Migraine is a life-span disease: it often begins at puberty and mostly affects people aged between 35 and 45 years, during their most active and productive years. It is common in children (about 10% of school-age children and up to 28% of adolescents between 15-19 years).

Migraine has a gender bias: women are more affected than men (8% men - 17.6% women).

Migraine impacts the individual's quality of life: depression and anxiety often coexist with migraine. Migraine can be a risk factor for dementia in women, is associated with chronic pain, and chronic pain substantially impacts the risk of memory decline and dementia.

Migraine is a neglected European challenge

Migraine is a neglected neurological disease that affects over 41 million people in the European Union (EU). It is labelled as the second leading cause of disability in the world and the third in people below 50.

The scope of the challenge is wide: migraine is under-diagnosed and under-treated. Being a life-span disease makes it a costly disease for the individual and society as a whole (indirect and direct costs such as reduced productivity and lost working hours, education).

Migraine is a neglected European challenge

Migraine is a neglected neurological disease that affects over 41 million people in the European Union (EU). It is labelled as the second leading cause of disability in the world and the third in people below 50.

The scope of the challenge is wide: migraine is under-diagnosed and under-treated. Being a life-span disease makes it a costly disease for the individual and society as a whole (indirect and direct costs such as reduced productivity and lost working hours, education).

Migraine research must be increased: despite its prevalence, migraine is often overlooked by key decision makers in terms of funding and research. It is not exactly known what causes migraine. Research must continue into genetics, environmental factors, lifestyle, brain chemical imbalances, family history and gender.

The lack of robust data around migraine is the reason why the scale of the public health problem may be underestimated. The burden of migraine for the healthcare systems can be overcome by effective and cost-effective solutions .

European Parliament Migraine Alliance

The EU added value in tackling migraine

Despite the number of people affected and the heavy toll of migraine on society, no specific attention has been paid to this disease at EU level. It is time to redress the situation.

Evidence shows that coordinated and sustained EU actions on diseases has brought significant improvement to the lives of EU citizens.

The EU has a clear added value in spearheading initiatives that will benefit patients and their families in each EU Member States.

Migraine is a major challenge today. All EU institutions have the power to address these challenges in a coordinated and ambitious way.

Why a Migraine Alliance in the European Parliament?

The European Parliament (EP) and its members have a pivotal role to play in tackling the migraine challenges.

The Migraine Alliance in the European Parliament is a non-exclusive, multi-national and cross-party group.

The Alliance will rally all Members of the European Parliament (MEPs) who agree to help steer policies and initiatives that will improve the quality of life of EU citizens, contribute to the sustainability of healthcare services and promote the inclusion of people with migraine at all levels (education, work, family life..).

Joining forces with the European Migraine and Headache Alliance and its 34 members at national level, the MEPs will help tackle these challenges by raising awareness and fostering cross-border EU collaboration.

The Alliance will foster strong EU and local action, shape political input for current and future legislation and integrate migraine into all relevant policies at all levels.

Why join the Migraine Alliance?

The members of the Migraine Alliance in the EP will have a prominent and visible role in addressing the challenges posed by migraine across the EU.

They will be invited to:

- Help raise awareness about migraine by facilitating a multi-stakeholder dialogue
- Trigger EU action on migraine (through the organisation of EP hearings, a EP Resolution on Migraine, written or oral questions to the Commission, regular events in the EP around specific themes)
- Support and contribute to the EU policy agenda and initiatives that will make a significant difference for people living with migraine
- Connect with the national migraine associations to raise awareness and influence policy at national level
- Help exchange of best practices between Member States

European Parliament Migraine Alliance

The Alliance's mission

- Raise awareness about the challenges of migraine at EU level
- Make migraine a European health, social and research priority
- Spread the political message that concerted action is needed in the field of prevention, diagnosis and treatment of migraine, research and social policies
- Promote actions that will make migraine a priority at European and national level
- Discuss how to influence the EU health, social and research agenda
- Rally strong and broad EU and national support through targeted initiatives
- Contribute to all EU future and on-going legislative proposals and programmes
- Be migraine Ambassadors at national level

Alliance modus vivendi

EMHA will hold the Alliance Secretariat. This will involve providing the Alliance members will all necessary information to support their commitment and actions.

EMHA will :

- Organise regular meetings with the Alliance members to decide on a yearly work plan
- Offer the Alliance members opportunities to learn directly from migraine medical and research experts and patients (public events or individual meetings)
- Be in charge of the organisations and follow-ups of meetings in the EP with the support of the Alliance members' office
- Provide all necessary information for the Alliance members to ease their engagement with the Alliance
- Give visibility to the Alliance members' engagement through interviews in the organisation's and members' newsletters, social media
- Provide substance for all Alliance members' activities at national or EU level (TV or radio interviews, articles...)

About EMHA

EMHA is a non-profit umbrella organization with 34 patient associations for Migraine, Cluster Headache, Trigeminal Neuralgia and other headache diseases, across Europe. The Alliance was launched in 2006. Its aim is to speak on behalf of and to advocate for the rights and needs of the 138 million people in Europe living with headache disorders. EMHA is an active member of the European Federation of Neurological Alliances [EFNA], the International Association of Patient Organizations [IAPO], the European Patients Forum [EPF] and also works closely with organizations such as the European Headache Federation [EHF], European Brain Council [EBC] and others

Contacts

Elena Ruiz de la Torre

Executive Director

elena@emhalliance.org

Annette Dumas

EU Affairs Associate

annette@emhalliance

+ 32 (0)473 22 18 54

<https://www.emhalliance.org/>

EU Transparency Register: 498061727237-52

Address: Rue d'Egmont 11 - 1000 Brussels (Belgium)

Email: communications@emhalliance.org

4#EUMigraineAlliance

#Migraine

@EMHAlliance

Resources

Agosti R., Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View, *Headache*, 2018; 58 :17-32 First published:26 April 2018 <https://doi.org/10.1111/head.13301>

Stovner L.J., Andre C., On behalf of the Eurolight Steering Committee, Impact of headache in Europe: a review for the Eurolight project, *J Headache Pain* (2008) 9:139–146 -

<https://doi.org/10.1007/s10194-008-0038-6>

WHO Headache Disorders Fact Sheet (2016), <https://www.who.int/news-room/factsheets/detail/headache-disorders>

Migraine and Research Foundation, <https://migraineresearchfoundation.org/about-migraine/migraine-in-kids-and-teens/>

Steiner T.J., Stovner L.J., Vos T., Migraine is the third cause of disability in under 50s, *J Headache Pain*. 2016; 17(1): 104. doi: 10.1186/s10194-016-0699-5

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108738/>

Atlas of headache disorders and resources in the world 2011 (2011), WHO – Lifting the Burden https://www.who.int/mental_health/management/atlas_headache_disorders/en/

Katsarava Z., Mania M., Lampl C., Herberhold J., Steiner T.J., Poor medical care for people with migraine in Europe – evidence from the Eurolight study, *J Headache Pain*. 2018; 19(1): 10.

<https://doi.org/10.1186/s10194-018-0839-1>

M. Linde et al., The cost of headache disorders in Europe: the Eurolight project, *European Journal of Neurology* 2012, 19: 703–e4, <https://doi.org/10.1111/j.1468-1331.2011.03612.x> European

Brain Council, Migraine Fact Sheet, <http://ebc-brussels.org/wp-content/uploads/2015/07/Migraine-fact-sheet-Sept-2011.pdf>

The Value of Treatment for Brain Disorders, Policy Paper – Towards Optimizing Research and Care for Brain Disorders, European Brain Council, (2017) https://www.braincouncil.eu/wp-content/uploads/2017/06/EBC_white_policy_paper_DEF26072017_Low.pdf

Schwedt T.J., Vo P, Fink R et al., Work productivity amongst those with migraine: results from the My Migraine Voice survey. Abstract presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS), San Francisco, CA, USA, June 28-July 1, 2018.

Steiner T.J., Stovner L.J., Katsarava Z., et al. The impact of headache in Europe: Principal results of the Eurolight project. *J Headache Pain*. 2014;15:31. DOI: 10.1186/1129-2377-15-31

The All-Party Parliamentary Group on Primary Headache Disorders (APPGPHD), Headache Disorders – not respected, not resourced. 2010. https://www.migrainetrust.org/wp-content/uploads/2015/12/2010Mar-APPGPHD_REPORT_Headache_Disorders-NotRespNotReso.pdf

Parikh S.K., Young W.B. Migraine: Stigma in Society. *Curr Pain Headache Rep*. 2019; 23(1):8. DOI: 10.1007/s11916-019-0743-7

Kostev K., Bohlken J., Jacob L., Association Between Migraine Headaches and Dementia in More than 7,400 Patients Followed in General Practices in the United Kingdom, *J Alzheimers Dis*. 2019;71(1):353-360. doi: 10.3233/JAD-190581.